Psoriasis, lichen planus, and disorders of keratinization: Unapproved treatments or indications

Clinics in Dermatology

Volumn 18, Issue 2, 2000, Pages 159-169

  Capella, Giovanni Luigi ^a   Finzi, Aldo Fabrizio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINONICOTINAMIDE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMETABOLITE; ANTITHYROID AGENT; AZARIBINE; AZATHIOPRINE; CACTINOMYCIN; CALCIPOTRIOL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUOROURACIL; HORMONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KERATOLYTIC AGENT; KETOCONAZOLE; MELPHALAN; MYCOPHENOLIC ACID; PODOPHYLLIN; RAZOXANE; RETINOIC ACID; RETINOID; SALAZOSULFAPYRIDINE; TIOGUANINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VITAMIN;

DARIER DISEASE; DRUG EFFICACY; DRUG INDICATION; DYSKERATOSIS; HUMAN; HYPERKERATOSIS; ICHTHYOSIS; KERATOSIS; KERATOSIS PALMOPLANTARIS; LICHEN PLANUS; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS; REVIEW;

DERMATOLOGIC AGENTS; DRUG APPROVAL; HUMANS; KERATOSIS; LICHEN PLANUS; PSORIASIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0034603486     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00106-6     Document Type: Review

References (187)

1. Li VW, Jaffe MP, Li WW, et al. Off-label dermatologic therapies. Usage, risks, and mechanisms. Arch Dermatol 1998;134:1449-54.
2. Bonnetblanc JM. J'AMMe, je RMOse, je trait [I RPHUSE, I RMR, I Treat]. Ann Dermatol Vénéréol 1997;124:597-8.
3. Cottone M, Rosselli M, Giunta M, et al. Quando non è possibile un trial clinico randomizzato [When a randomized clinical trial is not possible]. MEDIC (Rome) 1998; 6:153-7.
4. Barondess JA. The impossible in medicine. Perspect Biol Med 1986;29:521-9.
5. Camisa C. Psoriasis. Boston: Blackwell, 1994.
6. Degos R. Dermatologie. Paris: Flammarion, 1981.
7. Feldges DH, Barnes CJ. Treatment of psoriatic arthropathy with either azathioprine or methotrexate. Rheumatol Rehabil 1974;13:120-4.
8. Caccialanza P, Finzi AF. Clinical and experimental investigations on the effect of cytostatic drugs in psoriasis. Dermatology (Florence) 1974;11:37-46.
9. Caccialanza P, Finzi A. Terapia delle malattie cutanee e mucose. In: Zanussi C, editor. Terapia medica pratica. 4th ed. Turin: UTET, 1984:1057-75.
10. Zackheim HS, Maibach HI. 6-Thioguanine. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 2nd ed. New York: Dekker, 1991:589-92.
11. Calabresi P, Turner R, Lefkowitz ER. Beneficial effects of azarabine in psoriasis and mycosis fungoides. Proc Am Assoc Cancer Res 1964;5:10.
12. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469-75.
13. Alper JC, Weimann MC, Kegel M, et al. Outpatient 5-fluorouracil therapy for resistant psoriasis. Clin Res 1985; 33:622A.
14. Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis. J Am Acad Dermatol 1987;17:962-71.
15. Kragballe K. Experience with mycophenolate mofetil in severe recalcitrant psoriasis. In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:35.
16. Higgins LC Jr, Thompson JG. Psoriasis with arthritis: Chemotherapy with cyclophosphamide, nitrogen mustard, and six-mercaptopurine. South Med J 1966;59:1191-3.
17. Cerio R, Wells RS, MacDonald DM. The sequelae of razoxane therapy. Br J Dermatol 1985;113 (Suppl 29):27.
18. Stein KM, Shelley WB, Weinberg RA. Hydoxyurea in the treatment of pustular psoriasis. Br J Dermatol 1971;85: 81-5.
19. Shelley WB, Shelley ED. Advanced dermatologic therapy. Philadelphia: Saunders, 1987.
20. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1991;25:454-9.
21. Kaplin MH, Sadick NS, Wieder J, et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus associated psoriasis. J Am Acad Dermatol 1989;20:76-82.
22. Ruzicka T, Froschl M, Hohenleutner U, et al. Treatment of HIV-induced retinoid-resistant psoriasis with zidovudine (letter). Lancet 1987;2:1469-70.
23. Townsend BL, Cohen PR, Duvic M. Zidovudine for the treatment of HIV-negative patients with psoriasis: A pilot study. J Am Acad Dermatol 1995;32:994-9.
24. Horwitz JP, Chua J, Noel M. Nucleosides 5. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymine. J Org Chem 1964;29:2076-80.
25. Hay RJ, Champion RH, Greaves MW. Systemic therapy. In: Champion RH, Burton JL, Ebling FJG, editors. Rook/ Wilkinson/Ebling Textbook of Dermatology. 5th ed. Oxford, London: Blackwell, 1992:2927-60.
26. Zachariae H, Søgaard H, Nyfors A. Liver biopsy in psoriatics previously treated with potassium arsenite. Acta Derm Venereol (Stockh) 1974;54:235-6.
27. Weinstein GM, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol 1989;125: 227-30.
28. Reilly WG. Assessment of the antipsoriatic activity of Dermetrex™, a new topical lipophilic derivative of methotrexate (poster). In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:182-3.
29. Zackheim HS. Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. Arch Dermatol 1978; 114:1632-8.
30. Notowicz A, Stolz, Heuvel NVD. Treatment of Hallopeau's acrodermatitis with topical mechlorethamine (letter). Arch Dermatol 1978;114:1632-8.
31. Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. J Am Acad Dermatol 1986;14:761-4.
32. Rosenberg EW, Skinner RB Jr, Noah PW, et al. Treatment of psoriasis with clindamycin. In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:60.
33. Rosenberg EW, Skinner RB Jr, Noah PW. Antimicrobial treatment of psoriasis. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 2nd ed. New York: Dekker, 1991: 815-22.
34. Aubin F, Blanc D, Quencez E, et al. Pristinamycin as alternative therapy of generalized pustular psoriasis of pregnancy (letter). Dermatologica 1988;177:247-8.
35. Hone SW, Donnelly MJ, Powell F, et al. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol 1996;21:546-7.
36. Skinner RB, Rosenberg EW, Belew PW, et al. Improvement of psoriasis with cholestyramine. Arch Dermatol 1982;118:144.
37. 3: Rationale for its use in the treatment of psoriasis. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 2nd ed. New York: Dekker, 1991:791-807.
38. Ceder ET, Zon L. Treatment of psoriasis with massive doses of crystalline vitamin D and irradiated ergosterol. A preliminary report. Publ Health Rep (Washington) 1937;52:1580-4.
39. 3: A review of our experience. Arch Dermatol 1989;125:231-4.
40. Saurat JH. Retinoids and related compounds. In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:26.
41. Van Pelt JP, de Jong EM, de Bakker ES, et al. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis. Skin Pharmacol Appl Skin Physiol 1998;11:70-9.
42. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: An open study with liarozole. Br J Derm 1995; 133:426-32.
43. Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol 1988;124:854-5.
44. Altomare GF, Capella GL. Psoriasi instabile [Unstable psoriasis]. Ital Gen Rev Dermatol 1994;31:94-5.
45. Lahti A, Maibach HI. Systemic corticosteroids. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 2nd ed. New York: Dekker, 1991:559-62.
46. Hollander JL, Brown EM, Jessar, et al. The effect of triamcinolone on psoriatic arthritis. A two-year study. Arthritis Rheum 1959;2:513-25.
47. Braun-Falco O, Plewig G, Wolff HH. Dermatologie und Venerologie. 4th ed. Berlin: Springer, 1996.
48. Gligora M, Kolacio Z. Hormonal treatment of impetigo herpetiformis. Br J Dermatol 1982;107:253.
49. Camisa C. Somatostatin therapy. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 2nd ed. New York: Dekker, 1991:829-46.
50. Weber G, Neyhardt M, Frey H, et al. Treatment of psoriasis with bromocriptin. Arch Dermatol Res 1981;271: 437-9.
51. Elias AN, Goodman MM, Leim W, et al. Propylthiouracil in psoriasis - results of an open trial. J Am Acad Dermatol 1993;29:78-81.
52. Elias AN, Goodman MM, Rohan MK, et al. Methimazole (2-mercapto-l-methyl-imidazole) in psoriasis - results of an open trial. Dermatology 1993;187:26-9.
53. Ferrari VD, Jirillo A. Psoriasis and tamoxifen therapy: A case report. Tumori 1996;82:262-3.
54. Newman ED, Perruquet JL, Harrington TM. Sulfasalazine therapy in psoriatic arthritis: Clinical and immunologic response. J Rheumatol 1991;18:1379-82.
55. Farr M, Kitas GD, Waterhouse L, et al. Sulfasalazine in psoriatic arthritis: A double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
56. Gupta AK, Ellis CN, Siegel MT, et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 1990;126:487-93.
57. Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to Sulfasalazine. Am J Med 1982;73:520-4.
58. Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993;29:438-42.
59. Wahba A, Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol (Stockh) 1980;60: 515-20.
60. Ward JM, Corbett MF, Hanna MJ. A double-blind trial of clomocycline in the treatment of persistent palmoplantar pustulosis. Br J Dermatol 1976;95:317-22.
61. Grisham LM, Wilson L, Bensch K. Antimitotic action of griseofulvin does not involve disruption of microtubules. Nature 1973;244:294-6.
62. Nair LV, Shereef PH. Successful treatment of generalized pustular psoriasis with clofazimine (letter). Int J Dermatol 1991;30:151.
63. Ridley M. Pustular psoriasis. Br J Dermatol 1981;105 (Suppl 19):39-40.
64. Kragballe K. Dietary supplementation with a combination of n-3 and n-6 fatty acids (super gamma-oil marine) improves psoriasis. Acta Derm Venereol (Stockh) 1989; 69:265-8.
65. Kettler AH, Baughn RE, Orengo IF, et al. The effect of dietary fish oil supplementation on psoriasis. Improvement in a patient with pustular psoriasis. J Am Acad Dermatol 1988;18:1267-73.
66. Escobar SO, Achenbach R, Iannantuono R, et al. Topical fish oil in psoriasis - a controlled and blind study. Clin Exp Dermatol 1992;17:159-62.
67. Kragballe K, Herlin T. Benoxaprofen improves psoriasis. A double-blind study. Arch Dermatol 1983;119:548-52.
68. Lassus A, Forsstrom S. A dimethoxynaphthalene derivative (RS 43179 gel) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis. Br J Dermatol 1985;113:103-6.
69. Piraccini BM, Fanti PA, Morelli R, et al. Hallopeau's acrodermatitis continua of the nail apparatus: Clinical and pathological study of 20 patients. Acta Derm Venereol (Stockh) 1994;74:65-7.
70. Burns MK, Ellis CN, Eisen D, et al. Intralesional cyclosporine for psoriasis. Arch Dermatol 1992;128:786-90.
71. Wollenberg A, Bieber T. FK-506/Tacrolimus. In: Burg G, Dummer RG, editors. Strategies for immunointerventions in dermatology. Berlin, Heidelberg, New York: Springer, 1997:53-7.
72. Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506) a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992;128:781-5.
73. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996;132:419-23.
74. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus (FK506) is not effective in chronic plaque psoriasis. A pilot study. 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:137.
75. Mrowietz U. Macrolide compounds: A new promise for topical psoriasis therapy. In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:34.
76. Rappersberger K, Meingasser JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996;106:701-10.
77. Nestle FO. Rapamycin. In: Burg G, Dummer RG, editors. Strategies for immunointerventions in dermatology. Berlin, Heidelberg, New York: Springer, 1997:43-51.
78. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:1-7.
79. Thivolet J, Nicholas JF. Immunointervention in psoriasis with anti-CD4 antibodies. Int J Dermatol 1994;33:327-32.
80. Guzzo C. Recent advances in the treatment of psoriasis. Dermatol Clin 1997;15:59-68.
81. Marcusson JA, Wetterberg L. Peptide-T in the treatment of psoriasis and psoriatic arthritis. Acta Derm Venereol (Stockh) 1989;69:86-8.
82. O'Conell PG, Gerber LH, Digiovanna JJ, et al. Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol 1992;19:80-2.
83. Takematsu H, Ozawa H, Yoshimura T, et al. Systemic TNF administration in psoriatic patients: A promising therapeutic modality for severe psoriasis (letter). Br J Dermatol 1991;124:209-10.
84. Cristofolini M, Recchia G, Boi S, et al. 6-Methylangelicins: New monofunctional photochemotherapeutic agents for psoriasis. Br J Dermatol 1990;122:513-24.
85. Dubertret L, Averbeck D, Bisagny E. Photochemotherapy using pyridopsoralens. Biochimie 1985;67: 417-22.
86. Jillson OF. Psoriasis. Cutis 1982;29:230-42.
87. Fleischer AB Jr, Clark AR, Rapp SR, et al. Commercial tanning bed treatment is an effective psoriasis treatment: Results from an uncontrolled clinical trial. J Invest Dermatol 1997;109:170-4.
88. Swanbeck G. Psoriasis day care centers: European experience. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 2nd ed. New York: Dekker, 1991:553-6.
89. Nieboer C, deHoop D, Van Loenen AC, et al. Systemic therapy with fumaric acid derivatives: New possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989; 20:601-8.
90. Altmeyer P, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol 1994;30:977-81.
91. Thio HB, Van Der Schroeff JG, Nugteteren-Huying WH, et al. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol 1995;4:35-40.
92. Long PR, Milleu OF. Cimetidine and psoriasis (letter). Arch Dermatol 1981;117:523.
93. Witkamp L, Velthuis PJ, Verhaegh ME, et al. An open prospective trial with systemic ranitidine in the treatment of psoriasis. J Am Acad Dermatol 1993;28:778-81.
94. Sauder DN, Riviere M, Thibodeau A, et al. Angiogenesis antagonists as treatment for psoriasis: Phase 1 clinical trial results with AE-941. In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:39.
95. Polenghi MM, Molinari E, Gala C, et al. Experience with psoriasis in a psychosomatic dermatology clinic. Acta Derm Venereol (Stockh) 1991;186 (Suppl):65-6.
96. Lewis RS. Using art therapy in the treatment of psoriasis: A pilot study. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 3rd ed. New York: Dekker, 1998:815-31.
97. Walsh D. Using aromatherapy in the management of psoriasis. Nurs Standard 1996;11:53-6.
98. Jerner B, Skogh M, Vahlquist A. A controlled trial of acupunture in psoriasis: No convincing effect. Acta Derm Venereol (Stockh) 1997;77:154-6.
99. Parish LC, Lotti TM, editors. Balneology and the spa: The use of water in dermatology. Clin Dermatol 1996;14(6) (whole issue).
100. Weinrauch L. Climatotherapy of psoriasis. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 3rd ed. New York: Dekker, 1998:593-6.
101. 3 metabolism (letter). Acta Derm Venereol (Stockh) 1996;76:324-5.
102. Friedman SJ. Management of psoriasis with a hydrocolloid occlusive dressing. Arch Dermatol 1987;123: 1046-52.
103. Fisher LB, Maibach HI. Physical occlusion controlling epidermal mitosis. J Invest Dermatol 1972;59:106-8.
104. Gold MH, Roenigk HH Jr. Surgical treatment of psoriasis. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. 3rd ed. New York: Dekker, 1998:801-4.
105. Finnerty EF. Successful treatment of psoriasis of the nails. Cutis 1979;23:43-4.
106. Whittier FC, Evans DH, Anderson PC, et al. Peritoneal dialysis for psoriasis: A controlled study. Ann Intern Med 1983;99:165-8.
107. Boreham DR, Gasmann HC, Mitchel RE. Water bath hyperthermia is a simple therapy for psoriasis and also stimulates skin tanning in response to sunlight. Int J Hyperthermia 1995;11:745-54.
108. Jorstad S, Bergh K, Iversen OJ, et al. Effects of cascade apheresis in patients with psoriasis and psoriatic arthropathy. Blood Purif 1998;16:37-42.
109. Guillot B. Extracorporeal systems for the treatment of psoriasis. Plasma Ther Transf Technol 1987;8:143-6.
110. Willis I, Harris DR. Resistant psoriasis. Combined methoxsalen-anthralin therapy. Arch Dermatol 1973;107: 358-62.
111. Koo J. Calcipotriol/calcipotriene (Dovonex/Daivonex) in combination with photochemotherapy: A review. J Am Acad Dermatol 1997;37:S59-61.
112. Koo J. Systemic sequential therapy of psoriasis: A new paradigm for better therapeutic results. In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:47.
113. Van de Kerkhof PCM. Combinations and comparisons. Clin Dermatol 1997;15:831-4.
114. Lehrer A, Bressanell A, Wachsmann V, et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 1998;21:71-7.
115. Syed TA, Ahmad SA, Holt AH, et al. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study. Trop Med Int Health 1996;1:505-9.
116. Silva MC. ASF: A drug obtained from a natural product: Preparation, experimental evaluation and a clinical trial on psoriasis (poster). In: 5th European Congress on Psoriasis - 7th International Psoriasis Symposium Joint Meeting Abstract Book. Milan, 1998:164.
117. Fleischer AB Jr, Feldman SR, Rapp SR, et al. Alternative therapies commonly used within a population of patients with psoriasis. Cutis 1996;58:216-20.
118. Larkin M. "Personalised" drug therapy could be near. Lancet 1998;351:1937.
119. Eisen D, Ellis CN, Duell EA, et al. Effects of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. N Engl J Med 1990;323:290-4.
120. Sieg P, Von Domarus H, Von Zitzewitz V, et al. Topical cyclosporine in oral liehen planus: A controlled randomized, prospective trial. Br J Dermatol 1995;132:790-4.
121. Ho VC, Gupta AK, Ellis CN, et al. Treatment of severe lichen planus with cyclosporine. J Am Acad Dermatol 1990;22:64-8.
122. Schmitt EC, Pigatto PD, Boneschi V, et al. Erosiver Lichen planus der Glans penis. Behandlung mit Cyclosporin [Erosive lichen planus of the glans penis. Treatment with cyclosporin A]. Hautarzt 1993;44:43-5.
123. Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exp Dermatol 1996; 21:56-7.
124. Paslin DA. Sustained remission of generalized lichen planus induced by cyclophosphamide. Arch Dermatol 1985;121:236-9.
125. Snyder RA, Schwartz RA, Schneider JS, et al. Intermittent megadose corticosteroid therapy for generalized lichen planus. J Am Acad Dermatol 1982;6:1089-90.
126. Giustina TA, Stewart JC, Ellis CN, et al. Topical application of isotretinoin gel improves oral lichen planus. A double-blind study. Arch Dermatol 1986;122:534-6.
127. Bollag W, Ott F. Treatment of lichen planus with temarotene (letter). Lancet 1989;2:974.
128. 3 analogue KH 1060. Clin Exp Dermatol 1998;23:14-8.
129. Hodak E, Yosipovitch G, David M, et al. Low-dose low-molecular weight heparin (enoxaparin) is beneficial in lichen planus: A preliminary report. J Am Acad Dermatol 1998;38:564-8.
130. Ali A, Runzi M, Rosien U, et al. Lichen planus esophagitis with secondary candidiasis: Successful combination treatment with ketoconazole and a corticosteroid. Endoscopy 1996;28:460.
131. Sehgal VN, Bikhchandani R, Koranne RV. Histopathological evaluation of griseofulvin therapy in lichen planus. A double-blind controlled study. Dermatologica 1980;161:22-27.
132. Matthews RW, Scully C. Griseofulvin in the treatment of oral lichen planus: Adverse drug reactions, but little beneficial effects. Ann Dent 1992;51:10-1.
133. Naylor GD. Treating erosive lichen planus with griseofulvin: A report of four cases. Quintessence Int 1990;21: 943-7.
134. Massa MC, Rogers RS 3rd. Griseofulvin therapy of lichen planus. Acta Derm Venereol (Stockh) 1981;61547-50.
135. Abdel-Aal H, Abdel-Aal MA. Treatment of lichen planus with Bactrim. J Egypt Med Assoc 1976;59:547-9.
136. Wahba-Yahav AV. Idiopathic lichen planus: Treatment with metronidazole. J Am Acad Dermatol 1995;33:301-2.
137. Dereure O, Basset-Seguin N, Guilhou JJ, Erosive lichen planus: Dramatic response to thalidomide (letter). Arch Dermatol 1996;132:1392-3.
138. Joubert B, Devant O, Amblard P. La Disulone: Mise au point sur ses indications en dermatologie [Disulone: Focus on its indications in dermatology]. Ann Dermatol Vénéréol 1990;117:63-71.
139. Bogaert H, Sanchez E. Lichen planus: Treatment of thirty patients with systemic and topical phenytoin (letter). Int J Dermatol 1990;29:157-8.
140. Hildebrand A, Kolde G, Luger TA, et al. Successful treatment of generalized lichen planus with recombinant interferon alfa-2b. J Am Acad Dermatol 1995;33:880-3.
141. Engelmann L, Kunze J. Successful treatment of extensive lichen planus and ulcerous oral lesions with recombinant interferon-gamma (abstract). Arch Dermatol Res 1992; 284:20.
142. Qian SM, Chen YH. [Effects of diethyldithiocarbamate on interleukin-2 production of patients with oral lichen planus and its clinical therapeutic efficacy] [Chinese] Chung-Kuo Yao Li Hsueh Pao - Acta Pharmacologica Sinica 1991;12:378-80 (only Medline abstract retrievable).
143. Anderson R, Zeis BM, Anderson IF. Clofazimine-mediated enhancement of reactive oxidant production by human phagocytes as a possible therapeutic mechanism. Dermatologica 1988;176:234-42.
144. Engel MF. Indications and contraindications of the use of DMSO in clinical dermatology. Ann N Y Acad Sci 1967; 141:638-45.
145. Deasy PB, Collins AE, Burke FM, et al. In vitro and in vivo evaluation of a bondable compact for the prolonged delivery of triamcinolone acetonide to the oral cavity in patients with lichen planus. Pharma Acta Helv 1989;64: 276-9.
146. Kats AG, Volkova LA, Barabash AG, et al. Lechenie erozivno-iazvennoi formy krasnogo ploskogo lishaia nizkoenergeticheskim lazernym izlucheniem [Treatment of erosive-ulcerative forms of lichen planus with low-energy laser irradiation]. Vestn Khir Im II Grek 1990;144: 121-3 (only Medline abstract retrievable).
147. Goldstein JA. Liquen rojo piano tratado con shock anfetaminico [Lichen ruber planus treated with amphetamine shock]. Arch Argenti Dermatol 1968;18:173-5.
148. Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995;131:556-60.
149. Stuettgen G. Zur Lokalbehandlung von Keratosen mit Vitamin A-Säure. Dermatologica 1962;124:65-80.
150. Capella GL, Altomare GF, Frigerio E, et al. Cas pour diagnostic: Kératose pilaire rouge avec ulérythème ophryogéne [Case for diagnosis: Keratosis pilaris rubra with ulerythema ophryogenes]. Ann Dermatol Vénéréol 1998;125:61-2.
151. Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutaneous Pathol 1997; 24:416-24.
152. Hunter JA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol 1972;87:42-5.
153. Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 1994;31:997-9.
154. Binnick SA. Pityriasis rubra pilaris responding to aminonicotinamide. Arch Dermatol 1978;114:1348-9.
155. Clayton BD, Jorizzo JL, Hitchcock MG, et al. Adult pityriasis rubra pilaris: A 10-year case series. J Am Acad Dermatol 1997;36:959-64.
156. Griffiths WAD. Pityriasis rubra pilaris. Clin Exp Dermatol 1980;5:105-12.
157. Rosenbach A, Lowe NJ. Pityriasis rubra pilaris and cyclosporine. Arch Dermatol 1993;129:1346-8.
158. Meyer P, van Voorst PC. Lack of effect of cyclosporin A in pityriasis rubra pilaris. Acta Derm Venereol (Stockh) 1989;69:272.
159. Griffiths WAD, Hill V. Zidovudine in HIV-negative pityriasis rubra pilaris. J Dermatol Treat 1997;8:127-31.
160. Bergamaschini L, Tucci A, Colombo A, et al. Effect of stanozolol in patients with pityriasis rubra pilaris and retinol-binding protein deficiency. N Engl J Med 1982; 306:546-7.
161. Mainardi L, Caccialanza M, Piccinno R. Efficacia della fotochemioterapia in un caso di pityriasis rubra pilaris [Efficacy of photochemotherapy in a case of pityriasis rubra pilaris]. G Ital Dermatol Venereol 1990;125:537-8.
162. Brenner W, Gschnait F, Honigsmann H, et al. Erprobung von PUVA bei verschiedenen Dermatosen [The testing of photochemotherapy in various dermatoses]. Hautarzt 1978;29:541-4.
163. Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol 1990;22:792-5.
164. Griffiths WAD. Vitamin A and pityriasis rubra pilaris. J Am Acad Dermatol 1982;7:555.
165. Randle HW, Diaz-Perez JL, Winkelmann RK. Toxic doses of vitamin A for pityriasis rubra pilaris. Arch Dermatol 1980;116:888-92.
166. Murray JC, Gilgor RS, Lazarus GS. Serum triglyceride elevation following high-dose vitamin A treatment for pityriasis rubra pilaris. Cutis 1983;31:621-9.
167. Van de Kerkhof PCM, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol 1994;130:675-8.
168. Anthony TC. Brief clinical reports of two cases of pityriasis rubra pilaris. Aust J Dermatol 1960;5:185-6.
169. Watt TL, Jillson OF. Pityriasis rubra pilaris: Penicillin and antitubercolous drugs as possible therapeutic agents. Arch Dermatol 1965;92:428-30.
170. Ashurst PJC. The treatment of pityriasis rubra pilaris with Dipasic. Br J Dermatol 1962;74:372-5.
171. Tunnessen WW, Nieburg PI, Voorhess ML. Hypothyroidism and pityriasis rubra pilaris response to thyroid hormone. J Pediatr 1976;88:456-8.
172. Irgang S. Pityriasis rubra pilaris responsive to ascorbic acid. Aust J Dermatol 1968;9:211-7.
173. Lucker GP, Steijen PM, Suykerbuyk EJ, et al. Flow-cytometric investigation of epidermal cell characteristics in monogenic disorders of keratinization and their modulation by topical calcipotriol treatment. Acta Derm Venereol (Stockh) 1996;76:97-101.
174. Ayres S Jr, Myhan R. Keratosis folicularis (Darier's disease). Response to simultaneous administration of vitamins A and E. Arch Dermatol 1972;106:909-10.
175. Lykkesfeldt G, Høyer H. Topical cholesterol treatment of recessive X-linked ichthyosis. Lancet 1983;2:1337-8.
176. Ibsen HH, Brandrup F, Secher B. Topical cholesterol treatment of recessive X-linked ichthyosis. Lancet 1984; 2:645.
177. Thiers BH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol 1997;37:S69-71.
178. Stege H, Hoffmann B, Ruzicka T, et al. Topical application of tazarotene in the treatment of nonerythrodermic lamellar ichthyosis (letter). Arch Dermatol 1998;134:640.
179. Braun RP, Ramelet AA. Failure of cyclosporine in Netherton's syndrome (letter). Dermatology 1997;195:75.
180. Ho VC, Gupta AK, Ellis CN, et al. Cyclosporine in lamellar ichthyosis. Arch Dermatol 1989;125:511-4.
181. Klein E, Hahn GM, Solomon JA, et al. Exploration of antimitotic agents in the treatment of a congenital disease, ichthyosis linearis circumflexa. J Surg Oncol 1979; 11:85-8.
182. Manabe M, Yoshiike T, Negi M, et al. Successful therapy of ichthyosis linearis circumflexa with PUVA. J Am Acad Dermatol 1983;8:905-6.
183. Levi L, Beneggi M, Crippa D, et al. Erythrokeratodermia congenitalis progressiva symmetrica Gottron. Hautarzt 1982;33:605-8.
184. Altomare GF, Capella GL, Frigerio E, et al. The interplay between hyperkeratosis and immunodeficiency leads to an unusual spectrum of tinea lesions in Down's syndrome patients. J Eur Acad Dermatol Venereol 1997;9: 90-2.
185. Ward WH. Scabies norvegica. Treatment with metho-trexate. Australas J Dermatol 1971;12:44-51.
186. McCarthy JT. Junk pile of history? Cutis 1997;60:121.
187. Grant-Kels JM. Issues confronting medicine. Dermatol Clin 1993;11:231-2.